外陰膣カンジダ症治療薬の世界市場：市場規模 - 薬物クラス別、投与経路別、流通チャネル別、地域別展望、競合戦略、セグメント別予測（～2032年）

世界の外陰膣カンジダ症治療薬の市場規模は、2032年までに16億2,000万米ドルに達し、CAGRで4.61%の成長が予測されています。

外陰膣カンジダ症の有病率の上昇、アンメットニーズに対応できる新規医薬品の承認、関心を高めるための政府や非営利団体による取り組みなどが、市場成長の主な促進要因となっています。

当レポートでは、世界の外陰膣カンジダ症治療薬市場について調査し、市場力学、市場変数と展望、競合情勢、薬物クラス・投与経路・流通チャネル・地域別の市場分析、企業プロファイル等に関する情報を提供しています。

目次

第1章 イントロダクション

• 調査範囲
• 市場セグメント分析

第2章 調査手法

• 調査データソース
• 市場規模の推定
• データの三角測量

第3章 エグゼクティブサマリー

第4章 市場力学

• 促進要因、抑制要因、機会、課題の分析
  • 促進要因
  • 抑制要因
  • 機会
  • 課題
• 世界の外陰膣カンジダ症治療薬市場におけるCOVID-19の影響

第5章 市場変数と展望

• SWOT分析
  • 強み
  • 弱み
  • 機会
  • 脅威
• PESTEL分析
  • 政治情勢
  • 経済情勢
  • 社会情勢
  • 技術情勢
  • 環境情勢
  • 法的情勢
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入者の脅威
  • 競合企業間の敵対関係
• ヒートマップ分析

第6章 競合情勢

• 世界の外陰膣カンジダ症治療薬の製造拠点流通、販売エリア、製品タイプ
• 世界の外陰膣カンジダ症治療薬市場における合併・買収、パートナーシップ、製品発売、コラボレーション

第7章 世界の外陰膣カンジダ症治療薬市場：薬物クラス別（2019年～2032年、100万米ドル）

• クロトリマゾール
• フルコナゾール
• ケトコナゾール
• ナイスタチン
• テルビナフィン
• テルコナゾール
• その他

第8章 世界の外陰膣カンジダ症治療薬市場：投与経路別（2019年～2032年、100万米ドル）

• 静脈内
• 経口
• 局所

第9章 世界の外陰膣カンジダ症治療薬市場：流通チャネル別（2019年～2032年、100万米ドル）

• 病院薬局
• オンライン薬局
• 小売薬局

第10章 世界の外陰膣カンジダ症治療薬市場：地域別（2019年～2032年、100万米ドル）

• 世界の外陰膣カンジダ症治療薬の市場規模・市場シェア：地域別（2019年～2025年）
• 世界の外陰膣カンジダ症治療薬の市場規模・市場シェア：地域別（2026年～2032年）
• アジア太平洋
  • オーストラリア
  • 中国
  • インド
  • 日本
  • 韓国
  • その他のアジア太平洋
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • その他の欧州
• 中東・アフリカ
  • サウジアラビア王国
  • アラブ首長国連邦
  • その他の中東・アフリカ
• 北米
  • カナダ
  • メキシコ
  • 米国
• ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • その他の南米

第11章 企業プロファイル

• Astellas Pharma Inc.
  • 企業概要
  • 財務展望
  • 製品概要
  • 最近の開発
• Basilea Pharmaceutica Ltd.
• Bayer AG
• Bristol-Myers Squibb Company
• Cadila Pharmaceuticals
• Grupo Ferrer International S.A.
• Mycovia Pharmaceuticals, Inc.
• Pfizer, Inc.
• Scynexis, Inc.

第12章 略語一覧

第13章 参照リンク

第14章 結論

第15章 調査範囲

Global Vulvovaginal Candidiasis Treatment Market Overview:

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.

The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy. The size of the global market for vulvovaginal candidiasis treatments is anticipated to increase. An NCBI article claims that VVC is a frequent virus in women that affects millions of women annually all over the world. Rising illness burden, a strong growing pipeline with recent approvals of disease management medicines, and the introduction of novel pharmaceuticals like BREXAFEMME and VIVJOA are some of the main reasons propelling market growth.The rising prevalence of VVC disease, the approval of novel medications that can address unmet needs, and initiatives by the government and non-profit groups to raise awareness are some of the major drivers of business growth.

Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market:

The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals. The market for vulvovaginal candidiasis has quickly rebounded as a result of all these factors, and it is expected to keep expanding.

Scope of the Report:

• Market size available for years: 2019-2032

• Base year considered: 2021

• Forecast period: 2022-2032

• Segments covered: By Drug Class, By Route of Administration, By Distribution Channel

• Regions covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

• Companies Covered: Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc.

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

• By Drug Class: Based on the Drug Class, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Clotrimazole, Fluconazole, Ketoconazole, Nystatin, Terbinafine, Terconazole, Others.

• By Route of Administration: Based on the Route of Administration, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Intravenous, Oral, Topical.

• By Distribution Channel: Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

• By Region: The global industry was dominated by North America. The area is anticipated to continue to grow steadily during the projection period, maintaining its leadership position. High disease prevalence, rising patient awareness, rising healthcare costs, and the existence of significant players in the area can all be contributed to this dominance. The development of the regional market is also aided by new approvals, launches, and innovative government initiatives. Asia Pacific, on the other hand, is anticipated to experience the fastest growth rate during the anticipated years. The increased disease burden of VVC and rising testing rates are both responsible for the high growth rate. Positive developments include government healthcare coverage, increasing consumer awareness, and a desire to use medical services.

Table of Contents

1. Introduction

• 1.1. Scope of the report
• 1.2. Market segment analysis

2. Research Methodology

• 2.1 Research data source
  • 2.1.1 Secondary data
  • 2.1.2 Primary data
  • 2.1.3 SPER's internal database
  • 2.1.4 Premium insight from KOL's
• 2.2 Market size estimation
  • 2.2.1 Top-down and Bottom-up approach
• 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

• 4.1. Driver, Restraint, Opportunity and Challenges analysis
  • 4.1.1 Drivers
  • 4.1.2 Restraints
  • 4.1.3 Opportunities
  • 4.1.4 Challenges
• 4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market

5. Market variables and outlook

• 5.1. SWOT analysis
  • 5.1.1 Strengths
  • 5.1.2 Weaknesses
  • 5.1.3 Opportunities
  • 5.1.4 Threats
• 5.2. PESTEL analysis
  • 5.2.1 Political landscape
  • 5.2.2 Economic landscape
  • 5.2.3 Social landscape
  • 5.2.4 Technological landscape
  • 5.2.5 Environmental landscape
  • 5.2.6 Legal landscape
• 5.3. PORTER'S five forces analysis
  • 5.3.1 Bargaining power of suppliers
  • 5.3.2 Bargaining power of Buyers
  • 5.3.3 Threat of Substitute
  • 5.3.4 Threat of new entrant
  • 5.3.5 Competitive rivalry
• 5.4. Heat map analysis

6. Competitive Landscape

• 6.1 Global Vulvovaginal Candidiasis Treatment Manufacturing Base Distribution, Sales Area, Product Type
• 6.2 Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market

7. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class, 2019-2032 (USD Million)

• 7.1 Clotrimazole
• 7.2 Fluconazole
• 7.3 Ketoconazole
• 7.4 Nystatin
• 7.5 Terbinafine
• 7.6 Terconazole
• 7.7 Others

8. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration, 2019-2032 (USD Million)

• 8.1 Intravenous
• 8.2 Oral
• 8.3 Topical

9. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel, 2019-2032 (USD Million)

• 9.1 Hospital Pharmacy
• 9.2 Online Pharmacy
• 9.3 Retail Pharmacy

10. Global Vulvovaginal Candidiasis TreatmentMarket, By Region, 2019-2032 (USD Million)

• 10.1 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2019-2025)
• 10.2 Global Vulvovaginal Candidiasis TreatmentSize and Market Share by Region (2026-2032)
• 10.3 Asia-Pacific
  • 10.3.1 Australia
  • 10.3.2 China
  • 10.3.3 India
  • 10.3.4 Japan
  • 10.3.5 South Korea
  • 10.3.6 Rest of Asia-Pacific
• 10.4 Europe
  • 10.4.1 France
  • 10.4.2 Germany
  • 10.4.3 Italy
  • 10.4.4 Spain
  • 10.4.5 United Kingdom
  • 10.4.6 Rest of Europe
• 10.5 Middle East & Africa
  • 10.5.1 Kingdom of Saudi Arabia
  • 10.5.2 United Arab Emirates
  • 10.5.3 Rest of Middle East & Africa
• 10.6 North America
  • 10.6.1 Canada
  • 10.6.2 Mexico
  • 10.6.3 United States
• 10.7 Latin America
  • 10.7.1 Argentina
  • 10.7.2 Brazil
  • 10.7.3 Rest of South America

11. Company Profiles

• 11.1 Astellas Pharma Inc.
  • 11.1.1 Company details
  • 11.1.2 Financial outlook
  • 11.1.3 Product summary
  • 11.1.4 Recent developments
• 11.2 Basilea Pharmaceutica Ltd.
  • 11.2.1 Company details
  • 11.2.2 Financial outlook
  • 11.2.3 Product summary
  • 11.2.4 Recent developments
• 11.3 Bayer AG
  • 11.3.1 Company details
  • 11.3.2 Financial outlook
  • 11.3.3 Product summary
  • 11.3.4 Recent developments
• 11.4 Bristol-Myers Squibb Company
  • 11.4.1 Company details
  • 11.4.2 Financial outlook
  • 11.4.3 Product summary
  • 11.4.4 Recent developments
• 11.5 Cadila Pharmaceuticals
  • 11.5.1 Company details
  • 11.5.2 Financial outlook
  • 11.5.3 Product summary
  • 11.5.4 Recent developments
• 11.6 Grupo Ferrer International S.A.
  • 11.6.1 Company details
  • 11.6.2 Financial outlook
  • 11.6.3 Product summary
  • 11.6.4 Recent developments
• 11.7 Mycovia Pharmaceuticals, Inc.
  • 11.7.1 Company details
  • 11.7.2 Financial outlook
  • 11.7.3 Product summary
  • 11.7.4 Recent developments
• 11.8 Pfizer, Inc.
  • 11.8.1 Company details
  • 11.8.2 Financial outlook
  • 11.8.3 Product summary
  • 11.8.4 Recent developments
• 11.9 Scynexis, Inc.
  • 11.9.1 Company details
  • 11.9.2 Financial outlook
  • 11.9.3 Product summary
  • 11.9.4 Recent developments

12. List of Abbreviations

13. Reference Links

14. Conclusion

15. Research Scope